IgG4-related disease (IgG4-RD) is a chronic inflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells, leading to fibrosis and organ dysfunction. As per Haralampos M. Moutsopoulos et al., 2025, the disease accounts for around 0.78-1.39 cases per 100,000 person-years. The growing focus on targeted biologics and immunomodulatory therapies is driving innovation in IgG4-related disease therapeutics. According to the IgG4-related disease pipeline analysis by Expert Market Research, several novel therapeutic products are under development, with monoclonal antibodies and B-cell inhibitors showing promising potential for significant growth in the coming years.
Major companies involved in the IgG4 related disease pipeline analysis include Zenas BioPharma (USA), LLC, Acepodia Biotech, Inc., and others.
Leading drugs currently in the pipeline include ACE1831, PRG-1801, and others.
The drug pipeline for IgG4-related disease is expected to grow with increased clinical trials, rising R&D investments in monoclonal antibodies, and expanding regulatory focus on rare autoimmune conditions.
The IgG4 Related Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into IgG4 related disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for IgG4 related disease. The IgG4 related disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The IgG4 related disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with IgG4 related disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to IgG4 related disease.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Immunoglobulin G4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by chronic inflammation and fibrosis. It is caused by dysregulated B cell activity and can affect multiple organs simultaneously. It often mimics other conditions, complicating diagnosis. The disease arises when B cells overproduce IgG4 antibodies, leading to immune dysfunction and tissue damage over time.
IgG4-related disease treatment typically includes corticosteroids or B cell-targeting therapies to reduce inflammation and prevent organ damage. Recent advancements focus on more targeted biologics with fewer side effects than traditional treatments. In June 2024, UPLIZNA® (inebilizumab-cdon) became the first FDA-approved therapy for IgG4-related disease, targeting CD19+ B cells to reduce immune-driven inflammation.
Immunoglobulin G4-related disease is increasingly recognized as a rare but significant condition. According to Haralampos M. Moutsopoulos et al., 2025, the incidence is estimated at 0.78-1.39 per 100,000 person-years. As per Rare Diseases Advisor, U.S. epidemiologists found the point prevalence to be 5.3 per 100,000 persons in 2019. The mortality rate was reported as 3.42 per 100 person-years. According to Salma El Aouadi et al., 2025, Japan reports a prevalence of 6 to 30 per 100,000 individuals.
This section of the report covers the analysis of IgG4 related disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I and II covers a major share of the total IgG4 related disease clinical trials. They account for nearly 33%, reflecting strong clinical focus and development. Early phase I and phase III each contribute around 17%. This promising pipeline signals future breakthroughs, positively impacting treatment options and market growth.
The drug molecule categories covered under the IgG4 related disease pipeline analysis include monoclonal antibodies, small molecules, and peptides. The IgG4 related disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for IgG4 related disease. Bruton’s tyrosine kinase (BTK) inhibitors are gaining attention in the IgG4-related disease drug pipeline for their immune-modulating potential. For instance, rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation in the United States. It demonstrated promising results in reducing disease flare and dependency on glucocorticoids in a phase 2a clinical study involving IgG4-related disease patients.
The EMR report for the IgG4 related disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed IgG4 related disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in IgG4 related disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for IgG4 related disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of IgG4 related disease drug candidates.
ACE1831 is an allogeneic gamma delta T cell therapy developed by Acepodia Biotech, Inc., currently being evaluated for IgG4-related disease under a Phase 1b/2a clinical trial. This study aims to assess the safety, efficacy, and persistence of ACE1831 in affected individuals. The drug leverages bioorthogonal chemistry to attach CD20-targeting antibodies to T cells, offering a scalable, off-the-shelf alternative to autologous CAR-T therapies.
PRG-1801 is a BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapy, currently being evaluated for its safety and efficacy in patients with refractory lupus nephritis and IgG4-related disease. Sponsored by Tongji Hospital, this early Phase 1 trial aims to explore and expand dosing while assessing initial safety outcomes. Originally developed for multiple myeloma, PRG-1801 is now being repurposed for autoimmune conditions.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The IgG4 related disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for IgG4 related disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into IgG4 related disease collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share